Bulletin of Experimental Biology and Medicine

, Volume 88, Issue 4, pp 1106–1109 | Cite as

Effect ofβ-phenylethylamine on evoked potentials in the rat neostriatum

  • A. D. Zharikova
  • O. V. Godukhin
Physiology
  • 19 Downloads

Abstract

The effect of intraperitoneal (70 mg/kg) and local (39 μg) injections of β-phenylethylamine (βPEA) on evoked potentials (EP) in the caudate nucleus during stimulation of the compact zone of the substantia nigra in the frontal cortex was investigated in rats. For local application of βPEA, glutamate, and haloperidol a push-pull cannula system with simultaneous recording of EP was used. Definite specificity in the action of the drugs on EP of cortical and nigral origin was found. Intraperitoneal injection of βPEA caused a faster and stronger decrease in amplitude of the N2−P2 component in the response to stimulation of the substantia nigra than local application, but had very little effect on the amplitude of EP in response to stimulation of the frontal cortex. It was shown by the use of haloperidol that the N2−P2 component of EP in response to stimulation of substantia nigra is dopaminergic in nature. It is suggested that endogenous βPEA may be a regulator of the function of dopaminergic neurons in the nigro-neostriatal system of the rat brain.

Key Words

β-phenylethylamine dopamine evoked potential caudate nucleus substantia nigra frontal cerebral cortex 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature Cited

  1. 1.
    O. V. Godukhin and A. D. Zharikova, Fiziol. Zh. SSSR, No. 1, 141 (1979).Google Scholar
  2. 2.
    S. M. Antelman, D. J. Edwards, and M. Lin, Brain Res.,127, 317 (1977).Google Scholar
  3. 3.
    G. B. Baker, M. Raiteri, A. Bertollini, et al., J. Pharm. Pharmacol.,28, 456 (1976).Google Scholar
  4. 4.
    J. Divac, F. Fonnum, and J. Storn-Mathisen, Nature,266, 377 (1977).Google Scholar
  5. 5.
    D. A. Durden, S. P. Philips, and A. A. Boulton, Can. J. Biochem.,51, 995 (1973).Google Scholar
  6. 6.
    K. Fuxe, H. Crobecker, and J. Jonsson, Eur. J. Pharmacol.,2, 202 (1967).Google Scholar
  7. 7.
    W. J. Giardina, W. A. Pedemonte, and H. C. Sabelli, Life Sci.,12, 153 (1973).Google Scholar
  8. 8.
    K. Imatsubo and D. H. Clonet, J. Pharmacol. Exp. Ther.,202, 429 (1977).Google Scholar
  9. 9.
    T. Nakajima, Y. Kakimoto, and J. Sano, J. Pharmacol. Exp. Ther.,143, 319 (1964).Google Scholar
  10. 10.
    M. Raiteri, R. del Carmine, A. Bertollini, et al., Mol. Pharmacol.,13, 746 (1977).Google Scholar
  11. 11.
    H. C. Sabelli and W. J. Giardina, in: Chemical Modulation of Brain Function, New York (1973), p. 222.Google Scholar
  12. 12.
    H. C. Sabelli, A. J. Vazquez, and D. Flavin, Psychopharmacologia (Berlin),42, 117 (1975).Google Scholar
  13. 13.
    H. L. White and J. C. Wu, J. Neurochem.,25, 21 (1975).Google Scholar

Copyright information

© Plenum Publishing Corporation 1980

Authors and Affiliations

  • A. D. Zharikova
  • O. V. Godukhin

There are no affiliations available

Personalised recommendations